JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

A double-edged function of DDX3, as an oncogene or tumor suppressor, in cancer progression (Review).

Oncology Reports 2018 March
DEAD-box RNA helicase 3 (DDX3) is a highly conserved family member of DEAD-box proteins in all eukaryotes from yeasts to human beings. Accumulating studies have confirmed DDX3 has the ability to regulate different steps of RNA metabolism, including RNA splicing, RNA export, transcription and translation initiation. Moreover, DDX3 is involved in many biological processes, such as stress response, cell apoptosis, cell cycle regulation and virus infection. In recent years, DDX3 is getting increasing attention due to its essential roles in cancer progression. However, DDX3 role in cancer development is rather complicated. This review mainly focuses on the dual roles of DDX3 and DDX3-mediated signaling pathways in multiple cancers. In addition, the interplaying causes for the controversial roles of DDX3 in cancer are discussed. So far several small molecular chemical compounds targeting DDX3 are also summarized from the anticancer activity to the clinical trials of DDX3 inhibitors.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app